Clinical Analysis of 36 Cases with Primary Refractory Diffuse Large B Cell Lymphoma

Objective To investigate the survival ratio and factors affecting prognosis by analyzing clinical data. Methods Clinical data of 36 cases with primary refractory diffuse large B cell lymphoma admitted to Guangdong General Hospital were retrospectively analyzed. Results 5 patients refused further salvage treatment. First-line chemotherapy are anthracycline-based regimens combined with or without rituximab. The salvage treatment regimens are DICE, GDP, DHAP, CEPP, Lenalidomide and GA101. Median second progression free survival time is 1.7 months with 2 year second progression free survival rate being 5.0%. Median second overall survival time is 7.9 months with 2 year second overall survival rate being 25.9%. Univariate analyses showed that high IPI, bulky disease and B symptom influenced the prognosis. Conclusions Patients with primary refractory diffuse large B cell lymphoma have poor prognosis and can't benefit from regular salvage chemotherapy.